News | Molecular Imaging | July 02, 2015

Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals

Mevion S250 will be Ohio's first proton therapy system when operation begins in spring 2016

Mevion, S250, Seidman Cancer Center, University Hospitals, UH, proton therapy

July 2, 2015 - Mevion Medical Systems announced delivery of the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system for installation at University Hospitals (UH) Seidman Cancer Center and UH Rainbow Babies & Children's Hospital in Cleveland.

The accelerator is the core of the proton therapy system, and its installation is a crucial step in the deployment of the system at UH. The unit will be the first proton therapy system in Ohio treating adult and pediatric cancer patients when it begins clinical operation in the spring of 2016. This is the sixth accelerator delivery for Mevion.

"We are extremely excited to bring this leading-edge proton beam facility to Ohio," said Nathan Levitan, M.D., president of UH Seidman Cancer Center. "As a national leader in cancer care, University Hospitals Seidman Cancer Center is committed to providing patients with the most advanced cancer-fighting technology and treatments. The addition of the Mevion S250 will be a great complement to our existing state-of-the-art radiation oncology equipment and expertise and will benefit patients with many different types of cancer. Additionally, it provides a distinct advantage to our pediatric patients and their families at UH Rainbow Babies & Children's Hospital, eliminating the need to travel out of state for this technology, which results in fewer long-term effects due to the precisely targeted therapy."

Proton therapy is an advanced form of radiation therapy that targets cancer cells more directly while sparing much of the surrounding healthy tissue, thus making it ideal for treating pediatric patients as well as adults with cancer in sensitive locations such as near the heart or brain. Traditional proton therapy systems cost hundreds of millions of dollars to build and are typically the size of a football field. However, the Mevion S250 provides precise, effective and efficient treatment without the complexity of traditional systems. In addition, the capital costs and the operating costs are significantly less as the Mevion S250 requires less space, less staff and less energy than other proton systems.

Following the installation of the accelerator, the system will undergo proton beam tuning and acceptance testing to verify that it meets precise technical and clinical requirements before being commissioned for clinical use. It is expected to begin treating cancer patients in the spring of 2016. 

Currently, three Mevion S250 proton therapy systems are in clinical operation treating patients.

For more information: www.mevion.com

Related Content

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
The IBA Proteus Plus

The IBA Proteus Plus.

Feature | Proton Therapy | September 08, 2017 | By Jeff Zagoudis
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Overlay Init